Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 101–200 of 1,029
Ipp, E., Liljenquist, D., Bode, B., Shah, V. N., Silverstein, S., Regillo, C. D., Lim, J. I., Sadda, S., Domalpally, A., Gray, G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.34254 · Cited by 256
Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment
Abcouwer, S. F., & Gardner, T. W. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12412 · Cited by 254
“, NGF, IGFs, BDNF) bind their respective receptors (NTR), thus activating phosphoinositide 3-kinase (PI3K), resulting in formation of phosphoinositide(3,4,5)-trisphosphate (PIP3).”
BackgroundLi, Z., Keel, S., Liu, C., He, Y., Meng, W., Scheetz, J., Lee, P. Y., Shaw, J., Ting, D., Wong, T. Y., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0147 · Cited by 255
“6%, corresponding to nearly 100 million people worldwide (1).”
BackgroundSelf-citationDiabetic Retinopathy in the Context of Patients with Diabetes
Simó-Servat, O., Hernández, C., & Simó, R. (2019) · Ophthalmic Research · doi:10.1159/000499541 · Cited by 233
Pathophysiology of diabetic retinopathy: The old and the new
Kusuhara, S., Fukushima, Y., Ogura, S., Inoue, N., & Uemura, A. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0182 · Cited by 250
Integrated image-based deep learning and language models for primary diabetes care
Li, J., Guan, Z., Wang, J., Cheung, C. Y., Zheng, Y., Lim, L.-L., Lim, C. C., Ruamviboonsuk, P., Raman, R., Corsino, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03139-8 · Cited by 250
“Diabetic retinopathy (DR) is the most common specific complication of diabetes, affecting 30–40% of individuals with diabetes 11–13 , and remains the leading cause of blindness in economically active, working-aged adults 11,14,15 .”
Self-citationNovel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 239
Diabetic macular edema: Evidence-based management
Stewart, M., Browning, D., & Lee, C. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1240_18 · Cited by 237
Promising Artificial Intelligence-Machine Learning-Deep Learning Algorithms in Ophthalmology
(2019) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2018479 · Cited by 182
“1,15,16 Therefore, there is an urgent need for large-scale screening of DR to detect potentially threatening changes at an early stage that would benefit management and treatment.”
BackgroundAnimal Models of Diabetic Retinopathy
Olivares, A. M., Althoff, K., Chen, G. F., Wu, S., Morrisson, M. A., DeAngelis, M. M., & Haider, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0913-0 · Cited by 229
Hydrogels in ophthalmic applications
Kirchhof, S., Goepferich, A. M., & Brandl, F. P. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.016 · Cited by 229
Emerging roles of exosomal miRNAs in diabetes mellitus
He, X., Kuang, G., Wu, Y., & Ou, C. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.468 · Cited by 234
Diabetic macular edema: new concepts in patho-physiology and treatment
Zhang, X., Zeng, H., Bao, S., Wang, N., & Gillies, M. C. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-27 · Cited by 230
“According to the new meta analysis data in 2013, All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes [5].”
BackgroundMethodSelf-citationClassification of diabetic retinopathy: Past, present and future
Yang, Z., Tan, T.-E., Shao, Y., Wong, T. Y., & Li, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1079217 · Cited by 201
“Fifth, evaluation of systemic health is absent in current classifications, although it is clear that systemic factors such as diabetes duration, glycemic control, co-morbid hypertension and dyslipidemia, and even pregnancy, can influence DR progression and outcomes (3, 53, 54).”
BackgroundSelf-citationDiabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
Amoaku, W. M., Ghanchi, F., Bailey, C., Banerjee, S., Banerjee, S., Downey, L., Gale, R., Hamilton, R., Khunti, K., Posner, E., et al. (2020) · Eye · doi:10.1038/s41433-020-0961-6 · Cited by 216
lncRNA H19 prevents endothelial–mesenchymal transition in diabetic retinopathy
Thomas, A. A., Biswas, S., Feng, B., Chen, S., Gonder, J., & Chakrabarti, S. (2019) · Diabetologia · doi:10.1007/s00125-018-4797-6 · Cited by 213
Self-citationCost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore
Nguyen, H. V., Tan, G. S. W., Tapp, R. J., Mital, S., Ting, D. S. W., Wong, H. T., Tan, C. S., Laude, A., Tai, E. S., Tan, N. C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.08.021 · Cited by 218
Self-citationSex differences in micro- and macro-vascular complications of diabetes mellitus
Maric-Bilkan, C. (2017) · Clinical Science · doi:10.1042/cs20160998 · Cited by 217
Singh Grewal, A., Bhardwaj, S., Pandita, D., Lather, V., & Singh Sekhon, B. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150909143737 · Cited by 208
NRF2 plays a protective role in diabetic retinopathy in mice
Xu, Z., Wei, Y., Gong, J., Cho, H., Park, J. K., Sung, E.-R., Huang, H., Wu, L., Eberhart, C., Handa, J. T., et al. (2014) · Diabetologia · doi:10.1007/s00125-013-3093-8 · Cited by 210
“With an estimated prevalence of 93 million people, including 28 million with vision-threatening retinopathy, DR may become the leading cause of visual impairment in the world [2].”
S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression
(2017) · Springer eBooks · doi:10.1007/978-3-662-52906-5 · Cited by 210
Aberrant Expression of Long Noncoding RNAs in Early Diabetic Retinopathy
Yan, B., Tao, Z.-F., Li, X.-M., Zhang, H., Yao, J., & Jiang, Q. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13221 · Cited by 209
“Approximately one-third of diabetic patients have signs of DR and approximately one-tenth of patients have the vision-threatening phases of retinopathy, such as diabetic macular edema and proliferative retinopathy.(2) The pathogenesis of DR is multifactorial.”
BackgroundPrevalence of diabetic retinopathy within a national diabetic retinopathy screening service
Thomas, R. L., Dunstan, F. D., Luzio, S. D., Chowdhury, S. R., North, R. V., Hale, S. L., Gibbins, R. L., & Owens, D. R. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304017 · Cited by 202
Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies
Whitehead, M., Wickremasinghe, S., Osborne, A., Van Wijngaarden, P., & Martin, K. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1545836 · Cited by 198
“An estimated 285 million people suffer from diabetes, and one-third of these are affected by visionthreatening DR, which may include diabetic macular edema (DMO) or proliferative DR (pDR) [8].”
BackgroundEpidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action
El-Kebbi, I. M., Bidikian, N. H., Hneiny, L., & Nasrallah, M. P. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1401 · Cited by 186
Diabetes and retinal vascular dysfunction.
Shin, E. S., Sorenson, C. M., & Sheibani, N. (2015) · PubMed · doi:10.4103/2008-322x.143378 · Cited by 199
“81% for diabetic macular edema.[9] Impairment in vision due to DR remains a serious health issue worldwide.”
BackgroundKrawitz, B. D., Mo, S., Geyman, L. S., Agemy, S. A., Scripsema, N. K., Garcia, P. M., Chui, T. Y. P., & Rosen, R. B. (2017) · Vision Research · doi:10.1016/j.visres.2016.09.019 · Cited by 201
“Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults in developed countries (Zhang, Ferreyra, Grob, Bedell, & Zhang, 2013) and affects approximately 93 million people worldwide (Yau et al., 2012).”
BackgroundSingh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
“Literature evidence that, on average, ~35% of all diabetic patients suffer from some form of vision-related complications (Yau et al. 2012; Steinmetz et al. 2021).”
Retinal Vessel Segmentation Using Deep Learning: A Review
Chen, C., Chuah, J. H., Ali, R., & Wang, Y. (2021) · IEEE Access · doi:10.1109/access.2021.3102176 · Cited by 178
“tures, which are used to diagnose hypertension, diabetes, and atherosclerosis [1]–[4].”
BackgroundMicroaneurysm detection using fully convolutional neural networks
Chudzik, P., Majumdar, S., Calivá, F., Al-Diri, B., & Hunter, A. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2018.02.016 · Cited by 197
“One out of three diabetics has DR [3] and one in ten diabetic patients develops most vision-threatening form of DR [4].”
BackgroundZhao, Y., & Singh, R. P. (2018) · Drugs in Context · doi:10.7573/dic.212532 · Cited by 191
Chua, J., Chin, C. W. L., Hong, J., Chee, M. L., Le, T.-T., Ting, D. S. W., Wong, T. Y., & Schmetterer, L. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000001916 · Cited by 194
“In addition, hypertension is a risk factor for major eye disease such as diabetic retinopathy [7], age-related macular degeneration [8] and glaucoma [9].”
BackgroundSelf-citationOxidative stress and reactive oxygen species: a review of their role in ocular disease
Ung, L., Pattamatta, U., Carnt, N., Wilkinson-Berka, J. L., Liew, G., & White, A. J. R. (2017) · Clinical Science · doi:10.1042/cs20171246 · Cited by 192
Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction
Qiu, G.-Z., Tian, W., Fu, H.-T., Li, C.-P., & Liu, B. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.164 · Cited by 191
Presence and Risk Factors for Glaucoma in Patients with Diabetes
Song, B. J., Aiello, L. P., & Pasquale, L. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0815-6 · Cited by 163
“The higher rate of DR seen in type 1 diabetic patients is believed to be a result of the increased diabetes duration, hemoglobin A1c levels, and blood pressure typically observed in these patients [9].”
InfluentialCao, D., Yang, D., Huang, Z., Zeng, Y., Wang, J., Hu, Y., & Zhang, L. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1115-1 · Cited by 189
Self-citationZhang, S.-J., Chen, X., Li, C.-P., Li, X.-M., Liu, C., Liu, B.-H., Shan, K., Jiang, Q., Zhao, C., & Yan, B. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22698 · Cited by 188
“It still remains a leading cause of decreased vision and blindness globally.(1) The pathogenesis of DR has been extensively studied for many years.”
BackgroundDiabetes mellitus and hearing loss: A review
Samocha-Bonet, D., Wu, B., & Ryugo, D. K. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101423 · Cited by 178
“Aminoglycoside antibiotics, such as tobramycin, gentamicin, and amikacin, are implicated as the cause of hearing loss in more than 100,000 people annually (Zholudeva et al., 2015).”
BackgroundAnti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub6 · Cited by 184
Microvascular and macrovascular complications in children and adolescents
Donaghue, K. C., Wadwa, R. P., Dimeglio, L. A., Wong, T. Y., Chiarelli, F., Marcovecchio, M. L., Salem, M., Raza, J., Hofman, P. L., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12180 · Cited by 181
Self-citationRetinal Imaging Techniques for Diabetic Retinopathy Screening
Goh, J. K. H., Cheung, C. Y., Sim, S. S., Tan, P. C., Tan, G. S. W., & Wong, T. Y. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816629491 · Cited by 174
Self-citationArtificial Intelligence Screening for Diabetic Retinopathy: the Real-World Emerging Application
Bellemo, V., Lim, G., Rim, T. H., Tan, G. S. W., Cheung, C. Y., Sadda, S., He, M.-G., Tufail, A., Lee, M. L., Hsu, W., et al. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1189-3 · Cited by 176
Application of Random Forests Methods to Diabetic Retinopathy Classification Analyses
Casanova, R., Saldana, S., Chew, E. Y., Danis, R. P., Greven, C. M., & Ambrosius, W. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098587 · Cited by 177
“Diabetes duration and blood pressure are widely recognized as major DR risk factors [1].”
BackgroundRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
Advances in our understanding of diabetic retinopathy
Stitt, A. W., Lois, N., Medina, R. J., Adamson, P., & Curtis, T. M. (2013) · Clinical Science · doi:10.1042/cs20120588 · Cited by 177
Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy
Hu, J., Dziumbla, S., Lin, J., Bibli, S.-I., Zukunft, S., de Mos, J., Awwad, K., Frömel, T., Jungmann, A., Devraj, K., et al. (2017) · Nature · doi:10.1038/nature25013 · Cited by 172
Obeid, A., Su, D., Patel, S. N., Uhr, J. H., Borkar, D., Gao, X., Fineman, M. S., Regillo, C. D., Maguire, J. I., Garg, S. J., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.027 · Cited by 180
Pearce, I., Simó, R., Lövestam‐Adrian, M., Wong, D. T., & Evans, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13550 · Cited by 180
“Diabetic retinopathy (DR) is the most common complication of diabetes and remains the leading cause of blindness among working-age individuals in most developed countries.(1,2) DR has long been considered a microvascular complication of diabetes; however, growing evi-”
BackgroundGlobal prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis
Cheloni, R., Gandolfi, S. A., Signorelli, C., & Odone, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022188 · Cited by 172
Li, J. Q., Welchowski, T., Schmid, M., Letow, J., Wolpers, C., Pascual-Camps, I., Holz, F. G., & Finger, R. P. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-019-00560-z · Cited by 179
“The Meta-analysis for Eye Disease (META-EYE) study group has provided pooled global data on the prevalence and major risk factors of DR [3] and reported a prevalence of 34.”
BackgroundInfluentialTelemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis
Shi, L., Wu, H., Dong, J., Jiang, K., Lu, X., & Shi, J. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305631 · Cited by 174
Diabetic Retinopathy: An Overview on Mechanisms, Pathophysiology and Pharmacotherapy
Ansari, P., Tabasumma, N., Snigdha, N. N., Siam, N. H., Panduru, R., Azam, S., Hannan, J. M. A., & Abdel‐Wahab, Y. H. A. (2022) · Diabetology · doi:10.3390/diabetology3010011 · Cited by 180
“One more pooled analysis carried out on individuals from population-based research around the globe also demonstrated a direct correlation of hypertension, along with other factors, with the occurrence of DR [58].”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Mookiah, M. R. K., Hogg, S., MacGillivray, T. J., Prathiba, V., Pradeepa, R., Mohan, V., Anjana, R. M., Doney, A. S., Palmer, C. N. A., & Trucco, E. (2021) · Medical Image Analysis · doi:10.1016/j.media.2020.101905 · Cited by 165
Diabetic retinopathy: Breaking the barrier
Eshaq, R. S., Aldalati, A. M. Z., Alexander, J. S., & Harris, N. R. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.07.001 · Cited by 169
“blood pressure, high cholesterol, pregnancy, elevated glycated hemoglobin-A1c (HbA1c) and tobacco use [2].”
BackgroundClinical Report Guided Retinal Microaneurysm Detection With Multi-Sieving Deep Learning
Dai, L., Fang, R., Li, H., Hou, X., Sheng, B., Wu, Q., & Jia, W. (2018) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2018.2794988 · Cited by 171
“D IABETIC Retinopathy (DR) is the leading cause of blindness globally and also the top reason of new cases of legal blindness among adults aged 20 to 74 years in the United States [1].”
BackgroundMinireview: Challenges and Opportunities in Development of PPAR Agonists
Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1427 · Cited by 168
Vascular complications of diabetes: A narrative review
Lu, Y., Wang, W., Liu, J., Xie, M., Liu, Q., & Li, S. (2023) · Medicine · doi:10.1097/md.0000000000035285 · Cited by 218
“[11] In contrast to the global prevalence, DR affects a slightly lower proportion of the diabetic population in the United States, with a prevalence of 28.5% and a proportion of 4.4% with threatened loss of vision.”
InfluentialFeldman-Billard, S., Larger, É., & Massin, P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.014 · Cited by 162
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Sun, B., Luo, Z., & Zhou, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01200-7 · Cited by 168
Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach
Vujosevic, S., & Simó, R. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-21769 · Cited by 165
Recent novel approaches to limit oxidative stress and inflammation in diabetic complications
Pickering, R. J., Rosado, C. J., Sharma, A., Buksh, S., Tate, M., & de Haan, J. B. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1016 · Cited by 160
“After 20 years of diabetes, more than 60% of patients will have DR.(81) Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR.”
BackgroundInfluentialDetection of Diabetic Eye Disease from Retinal Images Using a Deep Learning Based CenterNet Model
Nazir, T., Nawaz, M., Rashid, J., Mahum, R., Masood, M., Mehmood, A., Ali, F., Kim, J., Kwon, H.-Y., & Hussain, A. (2021) · Sensors · doi:10.3390/s21165283 · Cited by 166
“According to the World Health Organization (WHO), as the prevalence of diabetes increases rapidly in the coming years, the proportion of those with DR is estimated to grow to 33% [4,5].”
BackgroundRetinal Cell Damage in Diabetic Retinopathy
Zhou, J., & Chen, B. (2023) · Cells · doi:10.3390/cells12091342 · Cited by 184
“Some of these proteins have been reported to increase endothelial permeability or alter the tight junction and cell adhesion proteins [10,76,82].”
BackgroundDiabetes in South-East Asia: An update
Ramachandran, A., Snehalatha, C., & Ma, R. C. W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.011 · Cited by 158
“prevalence of diabetic retinopathy was considerably lower among South Asians compared to Caucasian populations [39].”
BackgroundPhenotypes and biomarkers of diabetic retinopathy
Cunha-Vaz, J., Ribeiro, L., & Lobo, C. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.03.003 · Cited by 165
Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy
Sabanayagam, C., Yip, W., Ting, D. S. W., Tan, G., & Wong, T. Y. (2016) · Ophthalmic Epidemiology · doi:10.1080/09286586.2016.1193618 · Cited by 159
“In Tokyo, 32% of those with type 2 diabetes were unaware of their DR status.59 In Singapore, while 90% of those with diabetes were aware of their diabetic status, more than 80% of those with DR were unaware of their DR status, including 25% of those with sight-threatening DR.60 Few studies have documented awareness of…”
BackgroundInfluentialSelf-citationLi, L., Lu, Q., Chen, W., Li, J., Li, C., & Zheng, Z. J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8193523 · Cited by 179
“Regarding vascular complications of diabetes, 35% of individuals with diabetes have some form of diabetic retinopathy (DR), 7% have proliferative DR (PDR), 7% have diabetic macular edema, and 10% are in vision-threatening stages [2].”
BackgroundWeakly-supervised localization of diabetic retinopathy lesions in retinal fundus images
Gondal, W. M., Kohler, J. M., Grzeszick, R., Fink, G. A., & Hirsch, M. (2017) · 2017 IEEE International Conference on Image Processing (ICIP) · doi:10.1109/icip.2017.8296646 · Cited by 155
“The estimated global prevalence of referable DR (RDR) among patients with diabetes is 35.4% [1].”
BackgroundInfluentialHou, X., Wang, L., Zhu, D., Guo, L., Weng, J., Zhang, M., Zhou, Z., Zou, D., Ji, Q., Guo, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39864-w · Cited by 183
“A lower prevalenceof any DR in China may be partly related to ethnic disparity, with Asians reported havinga lowerDR prevalence thantheHispanics 12 , Middle Easterners 12 , and Caucasians 1 , and that the diabetes epidemic commenced later in China than in some developed countries 14,15 .”
Self-citationIglicki, M., Busch, C., Zur, D., Okada, M., Mariussi, M., Chhablani, J. K., Cebeci, Z., Fraser-Bell, S., Chaikitmongkol, V., Couturier, A., et al. (2019) · Retina · doi:10.1097/iae.0000000000002196 · Cited by 160
The role of inflammation in diabetic eye disease
Mesquida, M., Drawnel, F., & Fauser, S. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00750-7 · Cited by 170
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 214
MALAT1: An Epigenetic Regulator of Inflammation in Diabetic Retinopathy
Biswas, S., Thomas, A. A., Chen, S., Aref-Eshghi, E., Feng, B., Gonder, J., Sadikovic, B., & Chakrabarti, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-24907-w · Cited by 158
Self-citationWang, Q., Zhang, X., Fang, L., Guan, Q., Guan, L., & Li, Q. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198343 · Cited by 167
“There are many complications of DM, such as diabetic retinopathy and diabetic nephropathy, that can lead to blindness and kidney failure[4, 5].”
BackgroundSelf-citationSantos, A. R., Ribeiro, L., Bandello, F. M., Lattanzio, R., Egan, C. A., Frydkjær-Olsen, U., García‐Arumí, J., Gibson, J. M., Grauslund, J., Harding, S. P., et al. (2017) · Diabetes · doi:10.2337/db16-1453 · Cited by 173
Self-citationSinclair, S. H., & Schwartz, S. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00843 · Cited by 170
“Of note, diabetic retinopathy is the leading cause of blindness in the adult working population (7, 9).”
BackgroundSchnichels, S., Paquet‐Durand, F., Löscher, M., Tsai, T., Hurst, J., Joachim, S. C., & Klettner, A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100880 · Cited by 161
Kong, M., Xie, K., Lv, M., Li, J., Yao, J., Yan, K., Wu, X., Xu, Y., & Ye, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110975 · Cited by 167
Retinal Vascular Endothelial Cell Dysfunction and Neuroretinal Degeneration in Diabetic Patients
Mrugacz, M., Bryl, A., & Zorena, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030458 · Cited by 174
Weiss, M., Sim, D. A., Herold, T., Schumann, R. G., Liegl, R., Kern, C., Kreutzer, T., Schiefelbein, J., Rottmann, M., Priglinger, S., et al. (2018) · Retina · doi:10.1097/iae.0000000000001892 · Cited by 155
The genetics of diabetic complications
Ahlqvist, E., van Zuydam, N. R., Groop, L., & McCarthy, M. I. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.37 · Cited by 162
Xiao, W., Chen, X., Yan, W., Zhu, Z., & He, M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014644 · Cited by 152
Gonadal Hormones and Retinal Disorders: A Review
Nuzzi, R., Scalabrin, S., Becco, A., & Panzica, G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00066 · Cited by 150
Bethel, M. A., Diaz, R., Castellana, N., Bhattacharya, I., Gerstein, H. C., & Lakshmanan, M. C. (2021) · Diabetes Care · doi:10.2337/dc20-1815 · Cited by 151
Diabetic retinopathy for the non-ophthalmologist
Fung, T. H., Patel, B., Wilmot, E. G., & Amoaku, W. M. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0792 · Cited by 151
Wong, S. L., & Wagner, D. D. (2018) · The FASEB Journal · doi:10.1096/fj.201800691r · Cited by 157
Tsao, H.-Y., Chan, P.-Y., & Su, E. C.-Y. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2277-0 · Cited by 136
Hormel, T. T., Jia, Y., Jian, Y., Hwang, T. S., Bailey, S. T., Pennesi, M. E., Wilson, D. J., Morrison, J. C., & Huang, D. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100878 · Cited by 158
“, 2014) and diabetic retinopathy (DR) (Yau et al., 2012)- are all associated with changes in ocular circulation, the increased functionality provided by OCTA is important.”
BackgroundTransfer Learning based Detection of Diabetic Retinopathy from Small DatasetPreprint
Hagos, M. T., & Kant, S. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1905.07203 · Cited by 169
“eventually be at risk of developing DR [3].”
BackgroundCheung, N., Wong, I. Y., & Wong, T. Y. (2014) · Diabetes Care · doi:10.2337/dc13-1990 · Cited by 166
Self-citationDexamethasone intravitreal implant in the treatment of diabetic macular edema
Dugel, P. U., Bandello, F. M., & Loewenstein, A. (2015) · Clinical ophthalmology · doi:10.2147/opth.s79948 · Cited by 159
“Diabetic macular edema (DME) affects an estimated 21 million individuals worldwide.(4) Once diabetic retinopathy progresses to macular edema, treatment is indicated to slow the rate of vision loss and improve the long-term prognosis.”
Sim, D. A., Keane, P. A., Rajendram, R., Karampelas, M. D., Selvam, S., Powner, M. B., Fruttiger, M., Tufail, A., & Egan, C. A. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.03.009 · Cited by 147
Song, Y. J., Huang, L., & Yu, J. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.11.001 · Cited by 151
A Social Geography of the City
David, L. (1982) · Cited by 147
Associations between diabetic retinopathy and systemic risk factors
Wat, N., Wong, R. L. M., & Wong, I. Y. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj164869 · Cited by 171
New insights into the ameliorative effects of ferulic acid in pathophysiological conditions
Ghosh, S., Basak, P., Dutta, S., Chowdhury, S., & Sil, P. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.02.028 · Cited by 154
Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese
Tatsumi, Y., & Ohkubo, T. (2017) · Hypertension Research · doi:10.1038/hr.2017.67 · Cited by 158
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.